Clinical Trial Search

Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…

Primary: Feasibility - Session Attendance — 5; 5 Participants

Primary: Change in Neurocognitive Functioning — -0.94; -0.81; -1.03; -0.51 Global Neurocognitive Z-Score — p=0.05

Primary: Change From Week 0 in Percentage of Blood Monocytes Expressing Surface Marker CD16 at 12 Weeks, as a Result of Treatment. — 1.14; 1.51 Fold change — p=0.39

Primary: Change From Baseline to Week 24 in Global Neuropsychological Performance — .24 units on a scale — p=0.0079

Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001

Primary: Change in Normalized Composite Neurocognitive Test Score at Week 48 From Baseline — 0.20; 0.26; 0.31 total neurocognitive z-score — p=0.60

Primary: Working Memory Assessed by Domain Deficit Score — .29; .21; .14; .26 Score on a scale — p=0.039

Primary: Change in Working Memory — 51.33; 43.15 mean T score on working memory tests — p=.013

Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244

Primary: Change in the Processing of Speed — 2.63; 6.06 units on a scale

Primary: Association of 11C-labelled PK11195 Uptake Using PET With Acute HCV and HIV Infection — 0.18; 0.22 binding potential ratio

Primary: Self-Perceived Need for Cognitive Training — 7.49; 3.34 score on a scale

Primary: Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview — 81; 67 Participants

Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale

Primary: Change in CSF Ceramide Between Baseline and Week 24 (C18:0 Levels) - Intent to Treat — -30.78; 4.16; -12.17; -30.56 ng/mL — p=0.893

Primary: Psychomotor Speed — 54.2; 60.4; 53.4 score on a scale — p=0.40

Primary: Neurocognition: Mean Score of Hopkins Verbal Learning Test (Total) at Baseline — 29.4; 31.1 score on a scale

Primary: Symptom Burden Score — 1.08; 1.06; 0.83; 0.71 score on a scale — p=0.02

Primary: Cognitive Function, Global Cognitive Score (Z-score) — 0.15; 0.19; 0.16; 0.25 z score — p=0.68

Primary: Change in Monocyte Surface Markers Expression (Expressed as Percentage), Following Treatment of Chronic HIV+/ HAART+ Subjects With Atorvastatin (T=12wks Versus T=0wk)…

Primary: Influx Constant (Ki) for 18F-FDOPA PET. — 0.01415; 0.01409; 0.01588; 0.01592 min-1

Primary: Percentage of Participants Completing the Study — 90 Percentage of participants

Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants

Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml

Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607

Primary: Change in Patient Health Questionnaire (PHQ)-9 — 5; 7 units on a scale

Primary: Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure) — 87.0; 95.0 Percentage of Participants — p=0.2331

Primary: Change in Breath Test — 28; 14 ppm

Primary: Neuropsychological Performance (KABC2) — 63.32; 61.13; 62.65 T scores from USA norms for this test — p=0.02